Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement. The post Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today? appeared first on InvestorPlace . More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”